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DNA-Encoded Fetal Liver Tyrosine Kinase 3 Ligand and
Granulocyte Macrophage-Colony-Stimulating Factor Increase
Dendritic Cell Recruitment to the Inoculation Site and
Enhance Antigen-Specific CD4! T Cell Responses Induced by
DNA Vaccination of Outbred Animals1
Waithaka Mwangi,2* Wendy C. Brown,* Harris A. Lewin,† Chris J. Howard,‡ Jayne C. Hope,‡
Timothy V. Baszler,* Patrick Caplazi,* Jeffrey Abbott,* and Guy H. Palmer*
DNA-based immunization is a contemporary strategy for developing vaccines to prevent infectious diseases in animals and
humans. Translating the efficacy of DNA immunization demonstrated in murine models to the animal species that represent the
actual populations to be protected remains a significant challenge. We tested two hypotheses directed at enhancing DNA vaccine
efficacy in outbred animals. The first hypothesis, that DNA-encoding fetal liver tyrosine kinase 3 ligand (Flt3L) and GM-CSF
increases dendritic cell (DC) recruitment to the immunization site, was tested by intradermal inoculation of calves with plasmid
DNA encoding Flt3L and GM-CSF followed by quantitation of CD1! DC. Peak DC recruitment was detected at 10–15 days
postinoculation and was significantly greater (p < 0.05) in calves in the treatment group as compared with control calves inoc-
ulated identically, but without Flt3L and GM-CSF. The second hypothesis, that DNA encoding Flt3L and GM-CSF enhances
immunity to a DNA vector-expressed Ag, was tested by analyzing the CD4! T lymphocyte response to Anaplasma marginalemajor
surface protein 1a (MSP1a). Calves immunized with DNA-expressing MSP1a developed strong CD4! T cell responses against A.
marginale, MSP1a, and specific MHC class II DR-restricted MSP1a epitopes. Administration of DNA-encoding Flt3L and GM-
CSF before MSP1a DNA vaccination significantly increased the population of Ag-specific effector/memory cells in PBMC and
significantly enhanced MSP1a-specific CD4! T cell proliferation and IFN-" secretion as compared with MHC class II DR-matched
calves vaccinated identically but without Flt3L and GM-CSF. These results support use of these growth factors in DNA vacci-
nation and specifically indicate their applicability for vaccine testing in outbred animals. The Journal of Immunology, 2002, 169:
3837–3846.
Vaccination using DNA-encoded Ags induces cellular andhumoral immunity against microbial pathogens (1–3).Cellular uptake and intracellular expression of the vac-
cine DNA allows prolonged expression of Ag, mimicking the ef-
fect of a live vaccine (4, 5). In addition to improved Ag delivery,
DNA vaccine vectors can be modified to enhance the early stages
of Ag processing, presentation, and priming of Ag-specific B and
T lymphocytes. Modifications to the vector itself, such as inclusion
of stimulatory CpG motifs (6), or insertion of cytokine genes to be
coexpressed with the vaccine Ag have been shown to dramatically
enhance MHC class I- (7) and class II- (8) dependent immune
responses and confer protection against virulent challenge (9). Un-
surprisingly, the immunogenicity of DNA vaccines and the ability
of modified vectors to enhance immunity have been tested primar-
ily in mice. Translating results from these murine models to the
outbred species that represent the actual populations to be pro-
tected by vaccination is a significant barrier to deployment of DNA
vaccines. In vivo studies in humans and cattle have demonstrated
that, in contrast to the studies in murine models, multiple inocu-
lations of high doses of DNA vaccine are required to induce sig-
nificant immune responses (10–12). In addition, these studies re-
vealed that individual vaccinates are low responders, even when
they carry the MHC alleles capable of presenting the DNA vac-
cine-encoded epitopes (10–12). Consequently, identifying DNA
vaccine modifications that enhance immunogenicity in outbred
species is a high priority.
We chose to focus on enhancing early events in Ag processing
and presentation. Increasing DC recruitment and activation at the
immunization site has been shown to enhance vaccine immuno-
genicity in both murine models (8, 9) and outbred species (13),
including humans (14). Specifically, administration of the hemo-
poietic growth factor fetal liver tyrosine kinase 3 ligand (Flt3L)3
alone or in combination with GM-CSF significantly expands the
number of dendritic cells (DC) in both mice and humans (15–20).
Testing of DNA vaccine vectors encoding Flt3L or, separately,
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GM-CSF, has been shown to enhance Ag-specific immunity in
mice (8, 9, 21–23). However, comparative experiments testing the
protection induced by a DNA vaccine encoding the Plasmodium
yoelli circumsporozoite protein revealed significant enhancement
by GM-CSF only in mice (9) and not in rhesus monkeys (24). To
date, the efficacy of DNA vaccines encoding Flt3L has not been
tested in any species other than mice (25, 26). The goal of the
present study was to test whether Flt3L and GM-CSF, incorporated
into a DNA vaccine vector, would increase DC recruitment and
result in enhanced Ag-specific immune responses, using calves as
the outbred species. Administering a combination of recombinant
Flt3L and GM-CSF proteins to mice has an additive effect on the
overall number of DC and Ag-capture efficiency is augmented in
DC generated using the combined cytokines (20). The ability of
DNA-encoded Flt3L and GM-CSF to increase DC recruitment to
the immunization site and to enhance Ag-specific immune re-
sponses has not been reported for any animal species.
To test whether DNA-encoded Flt3L and GM-CSF would en-
hance immunity against a DNA vaccine-encoded Ag, the gene
encoding the major surface protein (MSP)-1a of the rickettsia
Anaplasma marginale was selected (27, 28). A. marginale is the
most prevalent tick-borne pathogen of cattle worldwide and there
are currently no safe and effective vaccines available (29, 30).
Immunity against A. marginale is associated with a MHC class
II-restricted CD4! T cell response and MSP1a is targeted by the
protective response (31, 32). Importantly, a CD4! T cell epitope-
rich region in MSP1a has been identified (aa 251–366) and specific
MHC class II DR-restricted epitopes have been localized (52). This
mapping allows testing whether the Flt3L/GM-CSF treatment en-
hances T cell responses to specific epitopes in vaccinates with the
appropriate MHC class II alleles. In this manuscript, we report
testing the following hypotheses: 1) DNA-encoding Flt3L and
GM-CSF increases DC recruitment to the immunization site; and
2) DNA-encoding Flt3L and GM-CSF enhances CD4! T cell re-
sponses to MSP1a expressed in a DNA vaccine vector.
Materials and Methods
Plasmid construction and purification
Generation of a construct expressing bovine Flt3L has been described pre-
viously (33). To generate a construct expressing GM-CSF, the open-read-
ing frame encoding bovine GM-CSF was PCR-amplified from pTar-
getGM-CSF (34). The forward primer (5"-ATAGATATCATGTGGCTG
CAGAACCTGCTTCTCC-3") introduced an EcoRV restriction site (in
italics) at the 5" end and the reverse primer (5"-TATGGATCCTCACT
TCTGGGCTGGTTCCCAGC-3") introduced a BamHI restriction site (in
bold) at the 3" end. The EcoRV-BamHI fragment was ligated into EcoRV-
BamHI digested VR-1055 eukaryotic expression vector (Vical, San Diego,
CA) to generate pVRGM-CSF.
Two constructs, one encoding the full-length MSP1a and the other en-
coding a modified extracellular domain of MSP1a (MSP1aED) were gen-
erated. The open-reading frame encoding the full-length MSP1a was re-
leased from pVCL/MSP1! (11) by digestion with PstI and ligation into the
PstI-digested VR-1055. A construct containing the msp1! gene in the cor-
rect orientation was designated pVRMSP1!. To improve MSP1aED ex-
pression efficiency, the gene encoding MSP1aED was modified to increase
hydrophilicity and a secretion signal sequence was added. To increase
MSP1aED hydrophilicity, the MSP1a hydropathic profile was predicted by
using the algorithm of Hoffmann (www.ch.embnet.org/software/TMPRED
_form.html) and a potential membrane insertion domain (residues 133–158)
was deleted. To direct MSP1aED secretion, the human CD5 secretory signal
sequence was added (35). The open-reading frame encoding the MSP1aED
(residues 1–366) was PCR-amplified from a recombinant plasmid (pVAr1)
containing a genomic DNA fragment of the A. marginale (Virginia strain)
msp1! gene (27). The forward primer (5"-ATACTGCAGATGTCAGCA
GAGTATGTGTTCTACC-3") introduced a PstI restriction site (in bold) at the
5" end and the reverse primer (5"-TGGATCCTACTGTGTAGTAGTGTGTC
CGAAGG-3") introduced a BamHI restriction site (in italics) at the 3" end.
The CD5 signal sequence was PCR-amplified and the product was sub-
cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA) to generate
pCD5ss. The MSP1!ED gene was ligated inframe as a PstI-BamHI frag-
ment into PstI-BamHI-digested pCD5ss to generate pCD5ssMSP1aED.
The CD5ssMSP1!ED open-reading frame, encoding the modified MSP1aED
(MSP1aEDm), was released as an EcoRV-BamHI fragment and was ligated
into EcoRV-BamHI digested VR-1055 to generate pVRMSP1!EDm.
The pVRFlt3L, pVRGM-CSF, pVRMSP1!, and pVRMSP1!EDm con-
structs, as well as the unmodified VR-1055 vector, were amplified in DH5!
Escherichia coli cells (Life Technologies, Gaithersburg, MD) and large-
scale plasmid DNA was purified using an endo-free Plasmid Gigaprep kit
(Qiagen, Valencia, CA). The endotoxin content in the plasmid DNA prep-
arations was measured using a Limulus Amebocyte Assay kit (BioWhit-
taker, Walkersville, MD) and was #5 EU/mg in all samples.
Protein expression
Flt3L, GM-CSF, MSP1a, and MSP1aEDm were expressed in COS-7L cells
(Life Technologies) as previously described (33). The pVRFlt3L-trans-
fected COS-7L cell monolayer was incubated with a 1/200 dilution of a
murine anti-bovine Flt3 ligand peptide antiserum (33) in blocking buffer,
whereas the pVRGM-CSF-transfected COS-7L cell monolayer was incu-
bated with 5 "g/ml anti-bovine GM-CSF 20.1 mAb (VMRD, Pullman,
WA). The pVRMSP1!- and pVRMSP1!EDm-transfected COS-7L cell
monolayers were incubated with 5 "g/ml anti-MSP1a mAb Ana22B1 (27).
Duplicate plates were either reacted with a negative control peptide anti-
serum or isotype control mAb. Following washes in blocking buffer, the
monolayers were incubated with a 1/2500 dilution of alkaline phosphatase-
conjugated caprine anti-murine mAb (Tropix, Bedford, MA) in blocking
buffer. Following washes in blocking buffer, the alkaline phosphatase ac-
tivity was detected using Fast Red TR/Naphthol AS-MX substrate (Sigma-
Aldrich, St. Louis, MO). Stained cells were visualized and photographed
using an inverted phase contrast microscope model CK-2 (Olympus Opti-
cal, Tokyo, Japan). The microscope was also used to count pVRMSP1!-
and pVRMSP1!EDm-transfected COS-7L cells expressing the encoded Ag
and the counts were used to calculate expression efficiency.
To generate protein for biological assays or T cell proliferation assays,
COS-7L cell monolayers were transfected with the DNA constructs as
above and 1 day posttransfection, the transfection medium was replaced
with serum-free medium VP-SFM (Life Technologies) supplemented with
4 mM L-glutamine. Supernatants were harvested 96 h posttransfection and
concentrated 10-fold using a filter device with a 10-kDa molecular mass
cut-off (Millipore, Bedford, MA). To verify protein expression in the con-
centrated supernatants, serial dilutions of the supernatants were used to
generate dot blots that were then reacted with peptide-specific antiserum
or mAb.
Bioassays for FLt3L and GM-CSF
Biological activity of the COS-7L-expressed bovine Flt3L has been re-
ported previously (33). The COS-7L-expressed bovine GM-CSF was tested
for biological activity using PBMC from a neonatal calf. Briefly, PBMC
(1 $ 104 cells per well) were incubated in triplicate with dilutions of the
GM-CSF supernatant for 7 days at 37°C with 5% CO2 in a humidified
chamber. Supernatant from the COS-7L cells transfected with the VR-1055
vector was used as a negative control. The cells were radiolabeled with
0.25 "Ci/ml [3H]thymidine for the last 4 h and harvested using an auto-
mated cell harvester (Tomtec, Orange, CT), and counted with a liquid
scintillation counter. The mean [3H]thymidine incorporation (cpm% 1 SD)
was plotted against supernatant dilutions.
Induction of MSP1-specific CD4! T cell recall responses with
MSP1aEDm Ag
Induction of MSP1-specific T cell recall responses by the COS-7L-ex-
pressed MSP1aEDm Ag was verified by lymphocyte proliferation assays as
described (31). Briefly, CD4! T cell clones 87.2A1 and 93.4E4 (3 $ 104
cells per well; Ref. 31) generated from calves immunized with native
MSP1 were incubated in duplicate with serial dilutions of the MSP1aEDm
COS-7L supernatant and 2 $ 105 irradiated autologous PBMC for 3 days.
rMSP1a carboxyl region (0.2–10.0 "g/ml; Ref. 31) was used as a positive
control and supernatant from the COS-7L cells transfected with the VR-
1055 vector was used as a negative control. The cells were radiolabeled for
the last 18 h of culture with 0.25"Ci/ml [3H]thymidine and harvested as
described above. The mean [3H]thymidine incorporation (mean cpm % 1
SD) was plotted against supernatant dilutions.
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Immunization of calves
Six male Holstein calves (7-mo-old) seronegative for A. marginale were
used in this study. PBMC from these calves were tested in a proliferation
assay with A. marginale Ags and found to be nonresponsive. MHC class
II-DRB3 alleles were defined by PCR-restriction fragment length polymor-
phism analysis of exon 2 (36). The DRB3 alleles are as follows: for calf 18,
DRB3*24/*24, for calf 19, DRB3*16/*22, for calf 20, DRB3*16/*22, for
calf 21, DRB3*16/*24, for calf 23, DRB3*16/*24, and for calf 24,
DRB3*22/*24. The calves were allocated to three groups and inoculated
with 1 mg of each DNA construct or vector following the protocol sum-
marized in Table I. For each dose, multiple intradermal injections (200 "l
per site) were administered randomly in a defined area (within a radius of
10 centimeters) on the right flank region (immunization site) using a 25-
gauge needle. The calves were boosted with 2 mg of the pVRMSP1!EDm
construct or the VR-1055 vector at 8-wk intervals.
DC recruitment
Recruitment of DC to the skin was analyzed by immunohistochemistry
using cryosections generated from biopsies taken randomly from the im-
munization site. On day 1, preinoculation biopsies were taken from the left
flank region before DNA injection on the right flank region. Postinocula-
tion biopsies were taken from the right flank immunization site on days 5,
10, 15, and 20 using a 6-mm Uni-Punch Disposable Biopsy Punch (Premier
Medical Products, King of Prussia, PA). The skin biopsies were snap-
frozen and stored at&80°C. Cryostat sections (4–6 "m) were cut from the
frozen skin biopsies and sections (four per slide) were collected on charged
glass slides (Probe On Plus; Fisher, Pittsburgh, PA). Three slides were
generated from each biopsy, fixed in acetone for 10 min and air-dried for
10 min at room temperature. The sections were probed with 1 "g/ml
TH97A mAb (Monoclonal Ab Center, Washington State University, Pull-
man, WA) that recognizes the bovine ortholog of the CD1 determinant
strongly expressed on skin DC (37). An isotype-matched mAb and sec-
ondary Ab were included as negative controls. Following washes with
PBS, the slides were incubated with a ready-to-use Biotinylated Murine
Linking Reagent (Signet Laboratories, Dedham, MA), washed again and
incubated with a 1/10,000 dilution of streptavidin-alkaline phosphatase
conjugate (Life Technologies). Following washes with PBS, the alkaline
phosphatase activity was detected using Fast Red TR/Naphthol AS-MX
substrate (Sigma-Aldrich). The slides were washed with distilled water and
counterstained with hematoxylin. Stained skin sections were photographed
using a Zeiss Axioskop microscope (Zeiss, Jena, Germany) whereas CD1!
DC (with nuclei) were visualized and counted using a light microscope
(magnification, $40) fitted with an ocular grid. From each slide, DC were
counted in the superficial and deep dermis from an area of 1.28 mm2 and
the mean % 1 SD of the CD1! cells from the three slides generated per
biopsy was calculated. Only CD1! cells with clearly visible nuclei were
counted. The significance of the difference between means of the Flt3L/
GM-CSF-treated and the control groups, and the variation of the means
over time was analyzed by ANOVA followed by the Bonferroni pairwise
multiple comparison test. A value of p # 0.05 was considered significant.
Establishment of T lymphocyte lines
Short-term A. marginale-specific T lymphocyte lines were established sev-
eral times from PBMC of the DNA-immunized calves 13-mo postimmu-
nization as described previously (11, 31). Briefly, CD8! and $% T lym-
phocytes were depleted by incubating PBMC with CD8-specific mAb
7C2B and $% TCR-specific mAb GB21A (Monoclonal Ab Center, Wash-
ington State University), followed by immunomagnetic separation using
sheep anti-mouse IgG-coated Dynabeads (Dynal Biotech, Lake Success,
NY) as described (38). T lymphocyte lines were established from the
CD8&, $%& PBMC by stimulation with homogenate prepared from the
Florida (FL) strain of A. marginale. Briefly, 4 $ 106 CD8&, $%& PBMC
per well in 24-well plates (Costar, Cambridge, MA) were cultured for 7
days in a volume of 1.5 ml of complete RPMI 1640 medium (31) with 10
"g/ml A. marginale FL strain homogenate. Background proliferation was
lowered by subculturing cells, without Ag, to a density of 7.5 $ 105 cells/
well and cultured with 2 $ 106 irradiated (3000 rad) autologous PBMC as
a source of APCs. The T lymphocyte lines were maintained for 7 more
days and then assayed for Ag-dependent proliferation.
Cell surface phenotypic analysis
Differentiation markers on T lymphocyte lines were analyzed by indirect
immunofluorescence and flow cytometry as described (39). Bovine CD2,
CD3, CD4, CD8, CD14, CD21, and the $-chain of the $% TCR-specific
mAbs used have been described previously (31).
Proliferation assays
Proliferation assays were conducted as described (11, 31). Briefly, T lym-
phocyte lines (3 $ 104 cells) were cultured in triplicate wells of round-
bottom 96-well plates (Costar) for 3 days in a total volume of 100 "l of
complete medium containing Ag and 2$ 105 irradiated autologous PBMC
as APC. Ags consisted of A. marginale FL strain homogenate (0.4 to 10.0
"g/ml), rMSP1a carboxyl region (residues 242–540) expressed as a mal-
tose-binding protein (MBP) fusion protein (0.4 to10.0 "g/ml) (31), and the
COS-7L-expressed MSP1aEDm supernatant (1/10–1/6250 dilution). Pep-
tides F2.1-F2.5 and F3.1-F3.6 (0.4–10.0 "g/ml) were also included to test
whether the T lymphocyte lines recognize MSP1a CD4! T cell epitopes
defined by CD4! T cell lines and clones generated from calves immunized
with native MSP1 (52). The F2 and F3 peptides (30 mer overlapping with
10 residues) span the F2 (residues 334–444) and F3 (residues 424–540)
regions of the extracellular domain of MSP1a (27). These regions were
defined by dividing residues 242–540 into three fragments (F1-F3) of
'112 residues. COS-7L-expressed F2 and F3 proteins induced MSP1a-
specific recall responses and thus, F2 and F3 peptides were generated to
map T cell epitopes within these regions (52). Membranes prepared from
uninfected bovine erythrocytes (URBC), rMBP (New England Biolabs,
Beverly, MA), the supernatant from COS-7L cells transfected with the
VR-1055 vector, and peptide MSP2 P1 derived from the unrelated A. mar-
ginale MSP2 (40) were used as negative control Ags. Cells were radiola-
beled, harvested, and counted as above. Results are presented as the stim-
ulation index (SI), defined as the mean cpm of triplicate cultures of cells
plus Ag divided by the mean cpm of triplicate cultures of cells plus me-
dium. The significance of the differences in proliferation of T lymphocytes
from the Flt3L/GM-CSF plus Ag-treated and control groups was analyzed
by Student’s t test using cpm values. A value of p # 0.05 was considered
significant.
Detection of IFN-$ in supernatants of T lymphocyte lines
Short-term A. marginale-specific T lymphocyte lines were established as
above and then were restimulated for 72 h with autologous APC and A.
marginale FL strain homogenate (10 "g/ml), rMSP1a carboxyl region-
MBP fusion protein (10 "g/ml), and the MSP1aED COS-7L supernatant
(1/50 dilution); supernatants were tested for IFN-$ production by ELISA.
Controls consisted of supernatants from cell lines stimulated with mem-
branes prepared from uninfected bovine erythrocytes (10 "g/ml), rMBP
(10 "g/ml), and the VR-1055 COS-7L supernatant (1/50 dilution). The
bovine IFN-$ assay was performed using an ELISA kit (BOVIGAM; CSL,
Parkville, Victoria, Australia) according to the manufacturer’s protocol.
The IFN-$ activity in culture supernatants diluted 1/4–1/100 was deter-
mined by comparison with a standard curve obtained as described previ-
ously (39). The results are presented as units of IFN-$ per milliliter. The
significance of the differences in units of IFN-$ per milliliter secreted by T
Table I. DNA immunization protocol
Group Flt3L/GM-CSF ! MSP1aEDm VR-1055 ! MSP1aEDm Flt3L/GM-CSF ! VR-1055
Animal numbers B0019; B0021 B0020; B0023 B0018; B0024
DRB3a 16/22; 16/24 16/22; 16/24 24/24; 22/24
Day 1 treatmentb Flt3L ! GM-CSF VR-1055 Flt3L ! GM-CSF
Day 9 treatmentc MSP1aEDm MSP1aEDm VR-1055
aMHC class II-DRB3 alleles were defined by PCR-restriction fragment length polymorphism analysis of exon 2 (36).
b Calves were inoculated intradermally with DNA constructs encoding Flt3L and GM-CSF or vector alone.
c Calves were inoculated with DNA construct encoding Ag or vector alone at the same site where the cytokine constructs
were injected.
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lymphocyte lines established from the Flt3L/GM-CSF plus Ag-treated and
the control groups was analyzed by Student’s t test.
Detection of Ag-specific lymphocytes by ELISPOT
To detect MSP1a-specific T lymphocytes without in vitro expansion, IFN-
$-expressing cells in PBMC were quantified using an ELISPOT assay
13-mo postvaccination. Hybridomas CC302 and CC330 were derived from
BALB/C mice immunized with bovine IFN-$ using the protocol described
by Kwong et al. (41) for IL-10. Briefly, mice were inoculated three times
i.m. with plasmid-encoding bovine IFN-$ and boosted just before removal
of spleens with the same plasmid (CC302) or with recombinant bovine
IFN-$ protein (CC330) given i.p. The ELISPOT assays were conducted in
triplicate wells of MultiScreen-HA plates (Millipore). The wells were
coated with mouse anti-bovine IFN-$ mAb CC330 (0.8 "g/ml) in distilled
water and, after incubation for 2 h at room temperature, excess Ab was
removed by washing with PBS containing 0.05% Tween 20 (PBST). The
coated wells were blocked with PBS containing 1% BSA for 1 h at room
temperature. The plates were then washed with PBST and incubated at
room temperature with complete RPMI until cells were added. Freshly
isolated PBMC (5 $ 105 or 1 $ 106 cells/well) were added to each well in
50-"l volumes. Ags or control mitogens were then added in 50-"l vol-
umes. MSP1aEDm was tested using supernatants of pVRMSP1!EDm-
transfected COS-7L cells at a dilution of 1/40. PHA-L at a 1 "g/ml final
concentration plus 0.01 ng/ml recombinant human IL-12 plus 0.5 ng/ml
recombinant human IL-18 were used as a positive control as this combi-
nation has been shown to stimulate high levels of IFN-$ in bovine PBMC
FIGURE 1. A, Expression of bovine Flt3L in COS7L cells. Monolayers of COS-7L cell transfectants were assayed for Flt3L expression using a murine
anti-bovine Flt3L peptide serum by in situ immunocytochemistry. Aa and Ab, COS-7L cells transfected with the pVRFlt3L construct encoding bovine Flt3L; Ac,
COS-7L cells transfected with empty vector; and Ad, COS-7L cells. Aa, Ac, and Ad COS-7L cell monolayers were probed with the murine anti-bovine Flt3L
peptide serum, whereas Ab was probed with a negative control peptide antiserum (murine anti-Babesia bigemina rhoptry-associated protein-1c peptide antiserum).
B, Expression of bovine GM-CSF in COS7L cells. COS-7L cell transfectants were assayed for GM-CSF expression using a murine anti-bovine GM-CSF mAb
(GM-CSF 20.1) by in situ immunocytochemistry. Ba and Bb, COS-7L cells transfected with the pVRGM-CSF construct encoding bovine GM-CSF; Bc, COS-7L
cells transfected with empty vector; and Bd, COS-7L cells. Ba, Bc, and Bd COS-7L cell monolayers were probed with mAb GM-CSF 20.1, whereas Bbwas probed
with an isotype-matched negative control mAb. C, Expression of full-length A. marginaleMSP1a and MSP1aEDm in COS-7L cells. COS-7L transfectants were
assayed for MSP1a andMSP1aEDm expression using Ana22B1 mAb by in situ immunocytochemistry. Ca and Cb, COS-7L cells transfected with the pVRMSP1!
construct encoding full-length A. marginale MSP1a (Virginia strain); Ce and Cf, COS-7L cells transfected with the pVRMSP1!EDm construct encoding
MSP1aEDm; Cc and Cg, COS-7L cells transfected with empty vector; Cd and Ch, COS-7L cells. Ca, Cc–Ce, Cg, and Ch COS-7L cell monolayers were probed
with the Ana22B1 mAb, whereas Cb and Cf were probed with an isotype-matched negative control mAb.
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(42). The negative controls were supernatants of COS-7L cells at a dilution
of 1/40 and complete RPMI alone. The plates were wrapped loosely with
aluminum foil (43) and incubated for 36 h at 37°C with 5% CO2. Plates
were then washed six times with PBST, once with distilled water, six times
with PBST, and then twice using PBS. Biotinylated mouse anti-bovine
IFN-$ mAb CC302 (0.5 "g/ml) diluted in 1% BSA/PBS, was added and
the plates were incubated for 2 h at room temperature. Excess Ab was
removed by washing using PBST. Vectastain ABC peroxidase PK-4000 kit
(Vector Laboratories, Burlingame, CA) was mixed and 100 "l per well
added. After a 1.5-h incubation at room temperature, plates were washed
six times with PBST followed by two washes using PBS. The spots were
developed with AEC (Sigma-Aldrich) according to the manufacturer’s rec-
ommendations. Plates were dried overnight and read using an ELISPOT
reader and AID 2.9 software (AutoImmun Diagnostika, Strassberg, Ger-
many). For each animal, the mean of spots in negative control wells was
subtracted from the mean of spots in test wells to determine the number of
MSP1a-specific spot-forming cells. Results were presented as the number
of MSP1a-specific IFN-$ secreting cells per 106 PBMC (%SD) and the
data was analyzed by ANOVA with Bonferoni correction to identify sta-
tistical differences in treatment groups.
Results
Plasmid DNA expression of Flt3L and GM-CSF
Protein expression of Vical 1055-encoded Flt3L and GM-CSF
transfected into COS-7L cells was assessed by in situ immunocy-
tochemistry. Expression was detected in the pVRFlt3L and
pVRGM-CSF COS-7L cell transfectants but not the respective
negative controls (Fig. 1, A and B). Biological activity of the COS-
7L-expressed bovine Flt3L has been reported previously (33). The
COS-7L-expressed bovine GM-CSF was tested for biological ac-
tivity using PBMC. The supernatant from COS-7L cells expressing
the bovine GM-CSF, but not the supernatant from COS-7L cells
transfected with the VR-1055 vector, stimulated a dose-dependent
lymphocyte proliferative response (maximal SI ( 63, data not
shown).
Plasmid DNA expression of MSP1a and MSP1!EDm
Immunocytochemical detection using mAb Ana22B1 revealed ex-
pression in COS-7L cells transfected with either pVRMSP1! or
pVRMSP1!EDm (Fig. 1C). Analysis of protein expression effi-
ciency (total number of cells expressing protein/total number of
transfected cells$ 100) showed that the pVRMSP1! COS-7L cell
transfectants had an expression efficiency of #1%, whereas the
pVRMSP1!EDm transfectants consistently had an expression ef-
ficiency )50% (Fig. 1C; data not shown). Dot blot analysis of
concentrated supernatants generated from the COS-7L cell trans-
fectants showed that MSP1!EDm was secreted but no MSP1a was
detected in supernatant generated from COS-7L cells transfected
with the pVRMSP1! construct (data not shown).
The COS-7L-expressed MSP1aEDm Ag, but not the supernatant
from COS-7L cells transfected with the VR-1055 vector, induced
dose-dependent Ag-specific proliferation of CD4! T cell clones
generated from calves immunized with native MSP1 (Fig. 2).
These CD4! T cell clones also proliferated in a dose-dependent
manner to purified MSP1a (clone 87.2A1, maximal SI( 50.7, and
clone 93.4E4, maximal SI ( 22.2). This result shows that the
MSP1aEDm Ag stimulates CD4! T cells primed using native
MSP1, and therefore bears epitopes represented on the native pro-
tein. Consequently, the pVRMSP1!EDm construct was chosen for
DNA immunizations.
Coadministration of DNA-encoded Flt3L and GM-CSF enhances
DC recruitment to a cutaneous inoculation site
Constructs expressing Flt3L and GM-CSF were coadministered
intradermally following the protocol summarized in Table I. DC
recruitment was analyzed by immunohistochemistry on biopsy
specimens using anti-CD1 mAb TH97A. There was an increase in
FIGURE 2. COS-7L expressed MSP1aEDm Ag in-
duces a CD4! T cell recall response by T cells from
native MSP1-immunized calves. Induction of MSP1-
specific T cell recall responses by the COS-7L-ex-
pressed MSP1aEDm Ag was verified by lymphocyte
proliferation assays using MSP1-specific CD4! T cell
clones. A, clone 87.2A1; B, clone 93.4E4. E, COS-7L-
expressed MSP1aEDm Ag; !, supernatant from
COS-7L cells transfected with the VR-1055 vector.
Each point represents the mean of [3H]thymidine incor-
poration in cpm from three wells % SD.
FIGURE 3. Flt3L and GM-CSF enhance DC recruitment to the skin. Recruitment of DC to the skin was analyzed by quantitative immunohistochemistry
using anti-CD1 mAb TH97A. A, Cryostat section from a preinoculation biopsy probed with mAb TH97A; B, cryostat section from a day 10 biopsy probed
with mAb TH97A; C, cryostat section from a day 10 biopsy probed with an isotype-matched negative control mAb; and D, cryostat section from a day
10 biopsy probed with secondary biotin-labeled caprine anti-murine mAb.
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CD1! DC following treatment with the Flt3L/GM-CSF constructs
(Fig. 3). To demonstrate the kinetics of DC recruitment at the
cutaneous site after the treatment, the means of DC counts from
skin biopsies taken at various time points were calculated. Peak
numbers of DC at the inoculation site in Flt3L/GM-CSF-treated
calves were significantly greater ( p # 0.05) than those in control
calves or preinoculation biopsies (Fig. 4). Importantly, there were
no statistically significant increases in the numbers of skin DC at
the inoculation site of calves injected with the VR-1055 vector
alone.
Flt3L and GM-CSF enhance Ag-specific CD4! T cell responses
The ability of Flt3L and GM-CSF to enhance MSP1a-specific
CD4! T cell responses was assessed by proliferation assays using
short-term T cell lines depleted of CD8! and $% TCR! T lym-
phocytes. Cell surface phenotypic analysis by flow cytometry
showed that the T cell lines comprised )86% CD4! T cells, and
#1% CD8 and $% T cells (data not shown). The CD4! T cell lines
established from the Flt3L/GM-CSF-treated and MSP1aEDm-im-
munized calves had significantly higher proliferative responses
(SI ) 30) to both A. marginale FL Ag (10 "g/ml) and the COS-
7L-expressed MSP1aEDm (1/50 dilution) supernatant compared
with proliferative responses (SI # 15) to the same Ags by the
CD4! T cell lines established from the calves immunized with
MSP1aEDm alone (Fig. 5). A similar difference in proliferative
responses to rMSP1a carboxyl region (10.0 "g/ml) as well as to
lower concentrations of all the Ags tested was observed (data not
shown). All CD4! T cell lines established from calves immunized
with the MSP1aEDm DNA construct, but not those established
from control calves, proliferated in a dose-dependent manner in
response to A. marginale FL strain homogenate (0.4 to 10.0 "g/
ml), rMSP1a carboxyl region (aa 242–767) expressed as an MBP
fusion protein (0.4–10.0 "g/ml) (31), and the COS-7L-expressed
MSP1aEDm supernatant (1/10–1/6250 dilution). There was no re-
sponse to membranes prepared from URBC, rMBP, and the su-
pernatant from COS-7L cells transfected with the VR-1055 vector
(data not shown). The MSP1a-specific proliferative responses of
CD4! T cell lines from the MSP1aEDm-immunized calves pre-
treated with Flt3L/GM-CSF were significantly higher than those of
MSP1aEDm-immunized calves that did not receive Flt3L/GM-
CSF ( p # 0.05). The responses of CD4! T cell lines from the
MSP1aEDm-immunized calves that did not receive Flt3L/GM-
CSF were significantly greater ( p # 0.05) than those of CD4! T
cell lines from the negative controls.
The ability of Flt3L and GM-CSF to increase the number of
Ag-specific effector/memory cells was tested by an IFN-$ ELIS-
POT assay using both 5 $ 105 and 1 $ 106 PBMC per well. The
number of MSP1a-specific cells in MSP1aEDm-immunized calves
pretreated with Flt3L/GM-CSF was significantly higher ( p #
0.05) than those of MSP1aEDm-immunized calves that did not
receive cytokines (Table II). Pairwise comparison between animals
with identical DR haplotypes in these two groups, B0019 with
B0020 (both are 16/22) and B0021 with B0023 (both are 16/24),
also demonstrated significantly higher ( p # 0.05) numbers of
MSP1a-specific effector/memory cells in the MSP1aEDm-immu-
nized calves pretreated with Flt3L/GM-CSF (Table II).
FIGURE 4. Kinetics of skin DC recruitment follow-
ing Flt3L and GM-CSF DNA inoculation. Holstein
calves were inoculated intradermally with a mixture of
pVRFlt3L and pVRGM-CSF (1 mg each) or with pVR-
1055 vector (2 mg). Data are presented as the mean %
SD of DC per 1.28 mm2 using anti-CD1 mAb TH97A
staining. The significance of the difference between
means of the treated and the control groups, and the
variation of the means over time was analyzed by
ANOVA followed by multiple pairwise comparison
tests with Bonferroni correction. !, Statistically signif-
icant differences (p # 0.05) between the Flt3L/GM-
CSF-treated calves and the vector control-treated calves
as well as between the postinoculation timepoint and
the preinoculation biopsies in the Flt3L/GM-CSF
treated calves.
FIGURE 5. DNA-encoded Flt3L and GM-CSF en-
hance CD4! T cell responses to MSP1a. CD4! T cell
lines established from each vaccinate were stimulated
for 72 h using 10 "g/ml A. marginale FL strain ho-
mogenate (f) and a 1/50 dilution of COS-7L-expressed
MSP1aEDm Ag (p). Negative controls included 10
"g/ml URBC membranes (") and a 1/50 dilution of
control supernatant (Sup. Ctrl) from COS-7L cells
transfected with VR-1055 vector (u). Results are pre-
sented as the SI. The significance of the differences in
CD4! T cell line response (counts per minute) to all the
Ags tested was analyzed by ANOVA followed by mul-
tiple pairwise comparison tests with Bonferroni correc-
tion and using p # 0.05. This assay was repeated three
times with similar results.
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The CD4! T cell lines were also tested for their ability to rec-
ognize MSP1a CD4! T cell epitopes defined by CD4! T cell lines
and clones generated from calves immunized with native MSP1
(52). The CD4! T cell lines established from calves treated with
Flt3L/GM-CSF before MSP1aEDm immunization had signifi-
cantly higher proliferative responses to the MSP1a peptides than
CD4! T cell lines established from the calves immunized with
MSP1aEDm alone (Table III). These data confirmed that the CD4!
T cells induced by MSP1aEDm recognize epitopes that also stim-
ulate T cell responses upon native MSP1 immunization.
Flt3L and GM-CSF enhance IFN-$ production by
MSP1a-specific CD4! T cell lines
The ability of Flt3L and GM-CSF to augment IFN-$ production by
MSP1a-specific CD4! T cells was demonstrated by analyzing su-
pernatants from Ag-stimulated short-term MSP1a-specific CD4!
T cell lines. Significantly more ( p# 0.05) IFN-$ was produced by
CD4! T cell lines established from the Flt3L/GM-CSF-pretreated
and MSP1aEDm-immunized calves compared with that produced
by CD4! T cell lines established from the calves immunized with
MSP1aEDm alone (Fig. 6). Short-term cultures derived from the
negative control calves did not secrete significant amounts of
IFN-$ (Fig. 6). The negative control Ags, membranes prepared
from uninfected bovine erythrocytes (10 "g/ml), and the superna-
tant from COS-7L cells transfected with the VR-1055 vector (1/50
dilution) stimulated undetectable or minimal levels of IFN-$ pro-
duction from all cultures (Fig. 6).
Discussion
DNA-encoding Flt3L and GM-CSF significantly increased DC re-
cruitment to the immunization site. Interestingly, the peak recruitment
occurred starting at 10 days postinoculation, similar to the peak re-
cruitment at 9–14 days observed when recombinant soluble human
Flt3L was inoculated daily into mice (10 "g/day) or humans (10 "g/
kg/day) (15, 16). This similarity in peak recruitment between daily
administration of soluble Flt3L and a single inoculation of DNA vec-
tor-encoded Flt3L and GM-CSF likely reflects the kinetics of DC
expansion and trafficking following growth factor stimulation. Nota-
bly, the results demonstrate that growth factor delivery via a DNA
vaccine vector provided the levels of growth factors sufficient for
enhanced DC recruitment. Combining administration of soluble
rFlt3L and GM-CSF to mice has been shown to have an additive
effect on splenic DC recruitment (20). As experiments dissecting the
ability of DNA encoding each hemopoietic growth factor, Flt3L and
GM-CSF, vs the combination to recruit DC has not been reported for
any species, the experimental system described in this study can be
used to determine whether the effects are additive, or synergistic, at
the expression levels associated with a single DNA inoculation.
Table II. Enumeration of MSP1a-specific lymphocytes in PBMC of vaccinated calves
Group Animal
Average Number of IFN-$ Secreting Cells Per 106
PBMC (%SD)
5 $ 105 PBMC/well 1 $ 106 PBMC/well
Flt3L/GM-CSF ! MSP1aEDm B0019 359% 34a 264 % 7a
B0021 441% 17a 284 % 19a
MSP1aEDm B0020 40% 14 15 % 6
B0023 223% 90 183 % 7
Flt3L/GM-CSF B0018 4% 17 12 % 9
B0024 14% 25 27 % 7
a Significantly greater ( p # 0.05) than B0020, B0023, B0018, and B0024.
Table III. Response of CD4! T lymphocytes to defined MSP1a epitopes
Proliferative Responsea (SI) of CD4! T Cell Lines
Peptideb
Flt3L/GM-CSF !
MSP1aEDm VR-1055 ! MSP1aEDm
Flt3L/GM-CSF !
VR-1055
B0019
(16/22)c
B0021
(16/24)
B0020
(16/22)
B0023
(16/24)
B0018
(24/24)
B0024
(22/24)
MSP2 P1 0.7 3.1 0.8 1.8 0.5 1.4
F2–1 29.0 26.0 4.9 9.4 0.5 1.5
F2–2 43.8 26.2 8.7 7.8 1.2 1.9
F2–3 25.1 23.9 2.8 8.5 1.1 1.4
F2–4 30.2 29.0 7.0 6.9 1.8 2.5
F2–5 30.3 29.8 1.8 5.9 1.8 1.6
F3–1 1.7 12.1 4.1 3.6 1.1 2.3
F3–2 22.3 24.9 6.5 3.9 0.9 2.4
F3–3 26.1 26.9 6.0 5.8 1.9 1.2
F3–4 17.9 16.4 4.1 5.9 1.8 1.3
F3–5 33.9 28.8 1.3 11.7 1.0 1.8
F3–6 2.7 14.2 1.9 1.6 1.0 1.2
a CD4! T cell-enriched lines were tested in a 72-h proliferation assay with MSP1a peptides. Results are presented as SI. SI)
3.5 are indicated in bold.
b Peptides F2–1 to F2–5 and F3–1 to F3–6 represent MSP1a T cell epitopes as described and referenced in Materials and
Methods. The MSP2 P1 peptide is from an unrelated A. marginale protein and was used as a negative control.
c Bovine MHC class II-DRB3 alleles were defined by PCR-restriction fragment length polymorphism analysis of exon 2 (36).
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Most importantly, the administration of DNA-encoded Flt3L
and GM-CSF before MSP1a DNA immunization resulted in a sig-
nificant increase in the effector/memory lymphocyte population
and significant enhancement of CD4! T lymphocyte proliferative
responses upon restimulation with MSP1a. Priming and expansion
of the CD4! T cell population is the primary goal for an effective
A. marginale vaccine (29, 39). Critically, the MSP1a DNA vaccine
primed T cells are capable of recognizing A. marginale organisms
and native MSP1a, as well as the DNA vector-expressed immuno-
gen, indicating that such effector/memory T cells would be stim-
ulated in vivo following A. marginale challenge.
The enhancement of Ag-specific T cell responses following
administration of DNA vector-encoded Flt3L and GM-CSF in
calves is comparable to the efficacy reported for inbred mouse
strains. Administration of soluble rFlt3L to BALB/c and
C57BL/6 mice for 9 days followed by immunization with
chicken OVA enhances clonal expansion and proliferation of
Ag-specific T cells in vivo and in vitro (21). Similarly, coad-
ministration (9, 44) or coexpression (8, 45) of GM-CSF with Ag
significantly enhances specific CD4! T cell responses in mice.
Notably, the enhanced T cell proliferative responses were
accompanied by significantly higher levels of IFN-$ when
restimulated in vitro (21). In the present study, the dominant
proliferative response by MSP1a-specific CD4! T cell lines
established from calves inoculated with DNA-encoding Flt3L
and GM-CSF before MSP1a immunization was mirrored by
significantly greater ( p # 0.05) MSP1a-specific IFN-$ levels.
IFN-$ expression is associated with protection in A. marginale
vaccinates, most likely functioning through coordinated activa-
tion of macrophages and induction of IgG2, the most efficient
opsonizing IgG subclass in cattle (31, 39, 46–49). Consistent
with this function, the calves treated with Flt3L and GM-CSF
before MSP1aEDm immunization developed MSP1a-specific
IgG2 and had higher IgG2 titers than control calves immunized
with MSP1aEDm alone (data not shown).
Immunization using native MSP1 in adjuvant has been shown
to induce protection against virulent challenge (50, 51). The
predominant CD4! T cell response in calves immunized with
native MSP1 is directed against epitopes in the region between
aa 151–366 and specific conserved epitopes in this region are
represented by 11 overlapping peptides (52). Analysis of CD4!
T cell lines established from calves immunized using DNA-
encoded MSP1a demonstrated that, with a single exception
(peptide F3-1), administration of DNA-encoded Flt3L and GM-
CSF before MSP1a immunization resulted in dramatically en-
hanced proliferation upon peptide stimulation ex vivo (Table
III). The strong response to defined epitopes suggests that the
DNA vaccine strategy does mimic, at least in part, the epitope
specificity of the response induced by native MSP1 immuniza-
tion. Significantly, analysis of CD4! T cell clones has previ-
ously established that the recognition of peptide F2-5 is MHC
class II DR-restricted (52). The identity of the MHC class II DR
haplotypes between MSP1a DNA vaccinates in both groups
(inoculated with Vical 1055-expressing Flt3L and GM-CSF vs
inoculated with Vical 1055 alone before immunization) indi-
cates that the enhanced responses are attributable to the growth
factor treatment and are not reflections of differences in ability
of specific MHC class II molecules to present Ag.
In summary, we have demonstrated that, as hypothesized, DNA-
encoding Flt3L and GM-CSF increases DC recruitment to the im-
munization site and enhances CD4! T cell responses to MSP1a
expressed in a DNA vaccine vector. Although this is the first report
testing the efficacy of coadministered DNA-encoded Flt3L and
GM-CSF in any species, the primary significance is in document-
ing the effect on T cell responses in a species that represents one
of the actual target populations to be protected by DNA-based
immunization. Specifically for A. marginale vaccine development,
the results allow progression to testing whether the DNA-encoded
Flt3L and GM-CSF augments protection against virulent challenge
in MSP1a vaccinates. In addition, the )50-fold increase in Ag
expression resulting from modification of MSP1a to MSP1aEDm,
without loss of critical T cell epitopes, defines the msp1! gene
construct to be tested in DNA vaccine trials. More broadly, the
ability of DNA-encoded Flt3L and GM-CSF to enhance DC
recruitment and Ag-specific CD4! T cell responses provides an
FIGURE 6. Flt3L and GM-CSF enhance IFN-$ production by MSP1a-specific CD4! T cell lines. Short-term MSP1a-specific CD4! T cell lines were
stimulated for 72 h using 10 "g/ml A. marginale FL homogenate or a 1/50 dilution of COS-7L-expressed MSP1aEDm Ag. Negative controls included 10
"g/ml URBC and a 1/50 dilution of control supernatant from COS-7L cells transfected with VR-1055 vector. Supernatants were tested for IFN-$ production
by ELISA and results were presented as units per milliliter. The significance of the difference in IFN-$ production was analyzed by ANOVA followed by
multiple pairwise comparison tests with Bonferroni correction. !, Statistically significant differences (p # 0.05) between the calves treated with Flt3L/
GM-CSF before MSP1aEDm immunization and both the calves immunized with MSP1aEDm (without Flt3L/GM-CSF treatment) and the calves inoculated
with Flt3L/GM-CSF but without MSP1aEDm immunization. !!, Statistically significant differences (p # 0.05) between the calves immunized with
MSP1aEDm (without Flt3L/GM-CSF treatment) and the calves inoculated with Flt3L/GM-CSF but without MSP1aEDm immunization.
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opportunity to identify additive or synergistic effects of the two
hemopoietic growth factors on specific events in Ag uptake,
processing, and presentation in outbred animals.
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